课题基金 / 基金详情

项目摘要

项目成果

CRAIG E. CAMERON的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): This is an application for renewal of a grant to study picornavirus genome replication. Picornaviruses represent an existing and emerging threat to US public health. Although protein factors and genetic elements required for picornavirus genome replication are known and appear to be conserved, a clear understanding of the mechanisms employed to produce picornaviral RNA is lacking. The long-term objective of this program is to reconstitute picornavirus genome replication in vitro from purified components. We have achieved all of the major objectives of the previous funding period. In addition, we have solved the first crystal structure for a picornaviral 3CD protein, developed the technology to study 3C-RNA interactions by using nuclear magnetic resonance spectroscopy, and discovered that the 3CD protein has both pre- and post-replication functions. During the next funding period, we will continue our studies of picornavirus genome replication as well as explore our newly discovered function for 3CD by pursuing the following specific aims: (1) Define the mechanism of assembly and structural organization of the picornavirus VPg uridylylation complex by using molecular genetic, biochemical and biophysical approaches; (2) Define the molecular basis for sequence- and structure-specific RNA recognition by 3C by using nuclear magnetic resonance spectroscopy; and (3) Elucidate the function of 3CD in formation of replication complexes. PUBLIC HEALTH RELEVANCE: Picornaviruses represent an existing and emerging threat to US public health. Achievement of the goals of the application will provide novel targets and mechanisms for development of inhibitors to treat infections by picornaviruses, especially those for which vaccines are not available.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Enteroviral 2C protein as a therapeutic target
Enteroviral 2C protein as a therapeutic target
Core C: Enzymology Core
Optimizing nucleoside analog efficacy with novel exonuclease inhibitors
  • 批准号:
    10514274
  • 项目类别:
  • 资助金额:
    $627.12万
  • 财政年份:
    2022
  • 负责人:
    CRAIG E. CAMERON
  • 依托单位:
海外基金